3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Pancreatic Neoplasms
13
Colorectal Neoplasms
13
Neoplasm Metastasis
7
Small Cell Lung Carcinoma
4
Neuroblastoma
4
Lung Neoplasms
4
Sarcoma
3
Rhabdomyosarcoma
3
Colonic Neoplasms
3
Cholangiocarcinoma
3
Biliary Tract Neoplasms
3
Stomach Neoplasms
2
Sarcoma, Ewing
2
Rectal Neoplasms
2
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Esophageal Squamous Cell Carcinoma
2
Esophageal Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Carcinoma, Neuroendocrine
2
Carcinoma, Hepatocellular
2
Uterine Cervical Neoplasms
1
Triple Negative Breast Neoplasms
1
Solid Tumors
1
Rhabdomyosarcoma, Embryonal
1
Rhabdomyosarcoma, Alveolar
1
Refractory Solid Tumors
1
Recurrence
1
Pathologic Complete Response
1
Pancreatic Ductal Adenocarcinoma
1
Ovarian Neoplasms
1
Interventions
11-(2-methylpropyl)-12,13-dihydro-2-methyl-8-(pyrimidin-2-ylamino)-4H-indazolo(5,4-a)pyrrolo(3,4-c)carbazol-4-one
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Gastro-enteropancreatic neuroendocrine tumor
×
Irinotecan
×
30 days
×
Clear all
No trials found.